|
Fri, 03/28/2025 - 17:57 |
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research |
Dana Farber |
|
Fri, 03/28/2025 - 17:35 |
FDA Approves Qfitlia (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B |
Alnylam |
|
Thu, 03/27/2025 - 18:04 |
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Regulus Therapeutics |
|
Thu, 03/27/2025 - 04:51 |
Chugai Obtains Regulatory Approval for First Tablet for SMA, Evrysdi |
Chugai |
|
Thu, 03/20/2025 - 19:04 |
Caris Life Sciences Publishes Study Featuring the Largest Real-World Cohort of Tissue-Agnostic Indications Revealing Over 20 Percent of Patients Are Eligible for Pan-Cancer Therapies |
Caris Life Sciences |
|
Tue, 03/18/2025 - 21:51 |
Chugai Launches LUNSUMIO for Intravenous Infusion, a Bispecific Antibody for Relapsed or Refractory Follicular Lymphoma in Japan |
Chugai |
|
Wed, 03/05/2025 - 07:02 |
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary |
Alnylam |
|
Tue, 03/04/2025 - 01:45 |
Certain Genetic Alterations May Contribute to the Primary Resistance of Colorectal and Pancreatic Cancers to KRAS G12C Inhibitors |
American Associ... |
|
Tue, 02/25/2025 - 17:51 |
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough |
Trevi Therapeutics |
|
Thu, 02/20/2025 - 05:57 |
Chugai Obtains Regulatory Approval for Tecentriq for the Additional Indication of Alveolar Soft Part Sarcoma, an Ultra-rare Disease |
Chugai |
|
Mon, 02/17/2025 - 18:15 |
Radiation Plus Combination Immunotherapy May Help Preserve Bladder in Some Patients With Muscle-invasive Bladder Cancer |
American Associ... |
|
Mon, 02/17/2025 - 15:58 |
Some Kidney Cancer Patients Can Stop Combination Treatment After Two Years, Fox Chase Cancer Center Study Finds |
Fox Chase Cance... |
|
Tue, 02/04/2025 - 15:41 |
Preoperative immunotherapy could enhance breast cancer cure rates |
UTSouthwestern |
|
Mon, 01/27/2025 - 11:45 |
Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA (fecal microbiota, live jslm) |
Ferring Pharmac... |
|
Fri, 01/24/2025 - 17:09 |
Fox Chase Cancer Center Researchers Present Data on Use of Checkpoint Inhibitors and Test Measuring Their Benefit to Patients |
Fox Chase Cance... |
|
Sun, 01/19/2025 - 23:21 |
Phase 2 LITESPARK-003 results suggest continued study of novel first-line combo for advanced kidney cancer |
Dana Farber |
|
Fri, 01/17/2025 - 19:17 |
U.S. Food and Drug Administration Approves FoundationOneCDx as a Companion Diagnostic for OJEMDA (tovorafenib) to Treat the Most Common Form of Childhood Brain Tumor in Pediatric Patients |
Foundation Medicine |
|
Fri, 01/17/2025 - 05:27 |
Chugai Wins the MHLW Ministers Award at the Seventh Japan Medical Research and Development Grand Prize for the Discovery of an ALK-Positive Lung Cancer Treatment Alecensa |
Chugai |
|
Sat, 12/14/2024 - 01:55 |
Roswell Park Team Identifies Factors That Boost Effectiveness of Immunotherapy in Recurrent Ovarian Cancer |
Roswell Park Ca... |
|
Thu, 12/12/2024 - 01:11 |
Could Venetoclax Improve Outcomes of CAR T for Patients with Resistant B-Cell Lymphomas? New Insights at ASH |
Roswell Park Ca... |
|
Wed, 11/20/2024 - 15:15 |
Roswell Park Clinical Trial Points Toward Promising New Therapy for Most Aggressive Type of Breast Cancer |
Roswell Park Ca... |
|
Wed, 08/28/2024 - 05:10 |
Alecensa Approved in Japan for the Additional Indication of Adjuvant Treatment for People with ALK-Positive Early-Stage Non-Small Cell Lung Cancer |
Chugai |
|
Wed, 08/07/2024 - 13:27 |
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024 |
Alnylam |
|
Mon, 08/05/2024 - 21:27 |
India, USA, Europe, Russia, August 05, 2024: Global Pharma major Lupin Limited (Lupin) today announced the successful completion of a global Phase 3 clinical study of LUBT010, its biosimilar candidate to Lucentis. The study has achieved its primary endpoi |
Lupin |
|
Sat, 08/03/2024 - 23:07 |
FDA Approves First Gene Therapy to Treat Adults with Metastatic Synovial Sarcoma |
FDA |
